Drugs that contain Glycopyrrolate; Indacaterol Maleate
1. Utibron patents expiration
UTIBRON's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6521260 | NOVARTIS | Carrier particles for use in dry powder inhalers |
Jan, 2016
(8 years ago) | |
| US6582678 | NOVARTIS | Carrier particles for use in dry powder inhalers |
Apr, 2018
(6 years ago) | |
| US8658673 | NOVARTIS | BETA2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8796307 | NOVARTIS | Beta2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US7820694 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8067437 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8283362 | NOVARTIS | Beta-2-adrenoreceptor agonists |
Jun, 2020
(3 years ago) | |
| US8029768 | NOVARTIS | Treatment of respiratory diseases |
Apr, 2021
(3 years ago) | |
| US7229607 | NOVARTIS | Treatment of respiratory disease |
Apr, 2021
(3 years ago) | |
| US9962338 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8303991 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8048451 | NOVARTIS | Pharmaceutical compositions for inhalation |
Jun, 2021
(2 years ago) | |
| US9931304 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US7736670 | NOVARTIS | Method of making particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8580306 | NOVARTIS | Particles for use in a pharmaceutical composition |
Jun, 2021
(2 years ago) | |
| US8956661 | NOVARTIS | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof |
Jun, 2021
(2 years ago) | |
| US8435567 | NOVARTIS | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation |
Jun, 2021
(2 years ago) | |
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(4 years from now) | |
| US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Product(NP) | Oct 29, 2018 |
NCE-1 date: 02 July, 2015
Market Authorisation Date: 29 October, 2015
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER;INHALATION
More Information on Dosage
UTIBRON family patents
